Blue Jet Healthcare Q1 FY27 Share Price & Earnings Call Analysis
- Market cap
- ₹9,525 Cr
- P/E
- 40.55
- ROE
- 19.35%
- PEG
- 2.73
- Price to sales
- 10.75
- Debt to equity
- 0.03
- 52W high / low
- ₹674 / ₹327
- Sales growth (5Y)
- 13.68%
- EBITDA margin
- 30.62%
- Net profit margin
- 25.45%
- Promoter holding
- 73.15%
- Sales (last year)
- ₹886 Cr
Incorporated in 1968, Blue Jet Healthcare (earlier called Jet Chemicals Pvt Ltd) is a pharmaceutical and healthcare ingredient & intermediate company and the first manufacturer of saccharin and its salts (artificial sweeteners) in India.[1]
Guidance scorecard · Q1 FY27 call
What Blue Jet Healthcare Ltd's management guided
and where it ranks in Pharmaceuticals & Biotechnology
Pharmaceuticals & Biotechnology
RevenueQ1 FY27 call
20–40%- Robust order book and strong visibility for the next several quarters, especially in PI/API segment.
- Incremental sales of INR30 crores likely to be recognized next quarter, subject to goods in transit variances.
- 3 candidates expected to launch in FY27 in Contrast Media; ongoing pilot for high-intensity sweetener.
- 20+ high conviction NCE RFPs being tracked with potential materialization of ~20%.
- Expectation of at least 2 lateral entry programs to fructify in near to medium term with initial clinical/validation quantities.
- Capacity expansion at Vizag and Mahad projects will support growth in complex APIs and CDMO manufacturing.
- Sustainable secular growth in PI/API tied to strong prescription market and consistent order book.
2 more points from Blue Jet Healthcare Ltd's call on revenue
Create a free account to keep reading this call
MarginsQ1 FY27 call
FlatSee what Blue Jet Healthcare Ltd said on margins — free account, 30 seconds.
CapexQ1 FY27 call
Planned- Mahad Facility: Investment of about INR210 crores already spent, with an additional INR40 crores committed to complete this phase. It is a globally scaled manufacturing facility for contrast media intermediates, expected to commission later in 2026,…
- Vizag Facility: Secured ~100 acres, planning Phase 1 investment of ~INR1,000 crores over 3 years, focusing on expanding contrast media manufacturing, multipurpose finishing blocks, flexible capacities for lateral entries, high-intensity sweetener…
- R&D Center: New facility with focus on peptides, GLP-1 intermediates, biocatalysts, continuous manufacturing, flow synthesis, and complex synthetic pathways. First phase expected operational by August 2026, strengthening CDMO capabilities and accelerating…
- FY27 Capex Guidance: Around INR400 crores planned, consistent with prior guidance.
FundraisingQ1 FY27 call
See what Blue Jet Healthcare Ltd said on fundraising — free account, 30 seconds.
Order bookQ1 FY27 call
Rising- Blue Jet Healthcare Limited has a robust order book with good visibility for the next several quarters.
- The company is tracking approximately 20 high-conviction RFPs (Request for Proposals), mostly in the chronic therapy space, with the potential for diversification beyond the current portfolio.
- Of these 20 high-conviction opportunities, around 20% are expected to materialize into business.
- New opportunities include 4 programs progressing well with innovator companies, alongside existing commercial orders.
- The cardiovascular (PI/API) segment has strong order books and steady production visibility for at least the next 3-4 quarters.
2 more points from Blue Jet Healthcare Ltd's call on the order book
Create a free account to keep reading this call
Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Peers
Pharmaceuticals & Biotechnology companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | 40%+ | Up 2%+ | ₹556 Cr | 22.1 | |
| 2 | 40%+ | Up 0–2% | ₹215 Cr | 22.2 | |
| 3 | 40%+ | Flat | ₹16,144 Cr | — | |
| 4 | 40%+ | Flat | ₹6,072 Cr | 48.0 | |
| 5 | 40%+ | Flat | ₹40 Cr | — | |
| 6 | 20–40% | Up 2%+ | ₹50,220 Cr | 43.8 |
Sign up free to see every company in the sector ranking and track Blue Jet Healthcare Ltd.
Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology rankingFinancials of Blue Jet Healthcare Ltd
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Blue Jet Healthcare Ltd
Quarterly Results
Quarter-by-quarter operating performance
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 217 | 180 | 181 | 167 | 184 | 163 | 208 | 318 | 340 | 355 | 165 | 192 | 235 |
| Expenses + | 147 | 121 | 119 | 112 | 131 | 119 | 139 | 194 | 200 | 234 | 111 | 146 | 163 |
| Operating Profit | 70 | 59 | 63 | 55 | 53 | 44 | 69 | 124 | 140 | 121 | 55 | 47 | 71 |
| OPM % | 32% | 33% | 35% | 33% | 29% | 27% | 33% | 39% | 41% | 34% | 33% | 24% | 30% |
| Other Income + | 6 | 5 | 8 | -3 | 9 | 9 | 12 | 13 | 12 | 8 | 24 | 13 | 23 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 5 | 0 | 1 |
| Depreciation | 6 | 6 | 6 | 8 | 8 | 3 | 5 | 5 | 5 | 6 | 6 | 6 | 6 |
| Profit before tax | 70 | 58 | 64 | 44 | 54 | 49 | 77 | 132 | 147 | 123 | 69 | 54 | 87 |
| Tax % | 27% | 24% | 26% | 27% | 27% | 24% | 24% | 25% | 25% | 26% | 24% | 25% | 26% |
| Net Profit + | 51 | 44 | 48 | 32 | 40 | 38 | 58 | 99 | 110 | 91 | 52 | 40 | 64 |
| EPS in Rs | 2.92 | 2.54 | 2.76 | 1.85 | 2.29 | 2.18 | 3.36 | 5.71 | 6.35 | 5.26 | 3.01 | 2.32 | 3.71 |
Financials of Blue Jet Healthcare Ltd
Profit & Loss
Annual income statement trend
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Sales + | 538 | 499 | 683 | 721 | 712 | 1,030 | 947 |
| Expenses + | 325 | 292 | 434 | 502 | 481 | 652 | 653 |
| Operating Profit | 214 | 207 | 249 | 219 | 231 | 378 | 294 |
| OPM % | 40% | 41% | 36% | 30% | 32% | 37% | 31% |
| Other Income + | 6 | 9 | 19 | 24 | 18 | 46 | 69 |
| Interest | 7 | 5 | 3 | 1 | 0 | 0 | 6 |
| Depreciation | 18 | 20 | 22 | 25 | 28 | 18 | 24 |
| Profit before tax | 194 | 190 | 243 | 217 | 220 | 406 | 333 |
| Tax % | 25% | 26% | 25% | 26% | 26% | 25% | 25% |
| Net Profit + | 145 | 142 | 182 | 160 | 164 | 305 | 248 |
| EPS in Rs | 24,118.33 | 1,428.77 | 10.47 | 9.23 | 9.44 | 17.59 | 14.29 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 11% | 7% | 8% |
Financials of Blue Jet Healthcare Ltd
Balance Sheet
Capital structure and asset base
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 0.60 | 10 | 35 | 35 | 35 | 35 | 35 |
| Reserves | 198 | 330 | 487 | 647 | 811 | 1,098 | 1,325 |
| Borrowings + | 74 | 52 | 19 | 5 | 3 | 21 | 42 |
| Other Liabilities + | 92 | 142 | 173 | 176 | 211 | 263 | 239 |
| Total Liabilities | 364 | 534 | 713 | 862 | 1,059 | 1,418 | 1,641 |
| Fixed Assets + | 107 | 139 | 156 | 151 | 172 | 300 | 316 |
| CWIP | 2 | 3 | 3 | 30 | 147 | 89 | 301 |
| Investments | 26 | 37 | 94 | 189 | 250 | 187 | 252 |
| Other Assets + | 229 | 355 | 460 | 491 | 489 | 841 | 771 |
| Total Assets | 364 | 534 | 713 | 862 | 1,059 | 1,418 | 1,641 |
Financials of Blue Jet Healthcare Ltd
Cash Flows
Operating, investing and financing cash movement
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 122 | 137 | 146 | 142 | 241 | 46 | 334 |
| Cash from Investing Activity + | -45 | -61 | -76 | -147 | -264 | -35 | -276 |
| Cash from Financing Activity + | -72 | -21 | -56 | -4 | -2 | -19 | -31 |
| Net Cash Flow | 5 | 55 | 14 | -10 | -24 | -8 | 28 |
| Free Cash Flow | 106 | 85 | 125 | 83 | 68 | -34 | 115 |
| CFO/OP | 80% | 66% | 70% | 92% | 109% | 36% | 151% |
Financials of Blue Jet Healthcare Ltd
Ratios
Working capital efficiency and return ratios
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 80 | 105 | 121 | 121 | 91 | 124 | 131 |
| Inventory Days | 120 | 253 | 133 | 137 | 151 | 209 | 157 |
| Days Payable | 90 | 128 | 72 | 58 | 35 | 70 | 48 |
| Cash Conversion Cycle | 110 | 231 | 183 | 199 | 206 | 262 | 240 |
| Working Capital Days | 55 | 89 | 103 | 120 | 92 | 157 | 224 |
| ROCE % | 58% | 53% | 35% | 30% | 40% | 26% |
Guidance history
How Blue Jet Healthcare Ltd's guidance has moved, call by call
| Call | Revenue | Margins | Capex | Fundraising | Order book |
|---|---|---|---|---|---|
| Q1 FY27 call → | 20–40% | Flat | Planned | — | Rising |
| Q4 FY26 call → | 10–20% | Flat | Planned | — | Rising |
| Q3 FY26 call → | 10–20% | Flat | Planned | Planned | — |
| Q2 FY26 call → | 20–40% | Flat | Planned | — | Rising |
What management guided on each call, newest first. Not investment advice, and not a forecast of returns.
Momentum score · price trend
23 out of 100 — Cooling
Over the past year its share price has done worse than most of the stocks we track.
| Period | Share price change | Better than … of 1,910 stocks |
|---|---|---|
| Last 12 months | −22.7% | 33% |
| Last 6 months | +13.3% | 70% |
| Last 3 months | −17.8% | 22% |
The price is 50.2% below its all-time high of ₹1,010.2 (18 Jul 2025). Stocks more than 20% below their peak have their score halved, so 45 became 23.
How we calculate it
“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,910 Indian companies worth ₹500 Cr or more, with at least a year of prices).
The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Blue Jet Healthcare Ltd: 0.4 × 33 + 0.4 × 70 + 0.2 × 22 = 45, halved to 23 because the price is more than 20% below its all-time high.
Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.
Full methodology →This describes only how the share price has moved up to 29 Oct 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.
Continue your research
What Blue Jet Healthcare Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Lincoln Pharmaceuticals Ltd (Q2 FY27)
2,798.12 Lakhs increase (approximately 17.1% growth) . Key results statement takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement — and how it
- Alivus Life Sciences Ltd (Q2 FY27)
Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). Key investor presentation takeaways from Alivus Life Sciences Ltd's Q2 FY27 invest
- Strides Pharma Science Ltd (Q2 FY27)
Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) . Key investor presentation takeaways from Strides Pharma Science Ltd's Q2 FY27 investor presentation
- Laurus Labs Ltd (Q2 FY27)
2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY